Susquehanna International Group, LLP Glycomimetics Inc Transaction History

Susquehanna International Group, LLP

$568 Billion
Q1 2024

A detailed history of Susquehanna International Group, LLP transactions in Glycomimetics Inc stock. As of the latest transaction made, Susquehanna International Group, LLP holds 554,594 shares of GLYC stock, worth $183,016. This represents 0.0% of its overall portfolio holdings.

Number of Shares

554,594

Previous 111,491 397.43%

Holding current value

$183,016

Previous $263,000 532.32%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	BUY	$2.55 - $3.49 $1.13 Million - $1.55 Million	443,103 Added 397.43%	554,594 $1.66 Million
Q4 2023 Feb 14, 2024	BUY	$1.13 - $2.54 $125,984 - $283,187	111,491 New	111,491 $263,000
Q2 2023 Aug 11, 2023	SELL	$1.21 - $2.08 $60,548 - $104,083	-50,040 Reduced 54.33%	42,069 $73,000
Q1 2023 May 16, 2023	SELL	$1.25 - $4.05 $51,878 - $168,087	-41,503 Reduced 31.06%	92,109 $116,000
Q4 2022 Feb 14, 2023	BUY	$0.67 - $3.03 $89,520 - $404,844	133,612 New	133,612 $404,000

Q2 2022 Aug 15, 2022	SELL	$0.54 - $1.15 $16,211 - $34,525	-30,022 Reduced 63.02%	17,618 $11,000
Q1 2022 May 16, 2022	SELL	$1.0 - $1.58 $217,568 - $343,757	-217,568 Reduced 82.04%	47,640 $54,000
Q4 2021 Feb 14, 2022	BUY	$1.44 - $2.14 $266,194 - $395,593	184,857 Added 230.06%	265,208 $382,000
Q3 2021 Nov 15, 2021	BUY	$1.8 - $2.39 $38,253 - $50,792	21,252 Added 35.96%	80,351 $176,000
Q2 2021 Aug 11, 2021	BUY	$2.16 - $3.18 $5,268 - $7,756	2,439 Added 4.3%	59,099 $137,000
Q1 2021 May 17, 2021	BUY	$2.89 - $4.22 $32,665 - $47,698	11,303 Added 24.92%	56,660 $171,000
Q4 2020 Feb 16, 2021	SELL	$2.69 - $4.24 $46,835 - $73,822	-17,411 Reduced 27.74%	45,357 $171,000
Q3 2020 Nov 16, 2020	BUY	$3.07 - $5.0 $98,117 - $159,800	31,960 Added 103.74%	62,768 $193,000
Q2 2020 Aug 14, 2020	BUY	$2.06 - $3.76 $18,422 - $33,625	8,943 Added 40.9%	30,808 $116,000
Q1 2020 May 15, 2020	BUY	$1.83 - $5.41 $16,071 - $47,510	8,782 Added 67.13%	21,865 $50,000
Q4 2019 Feb 14, 2020	SELL	$4.03 - $6.5 $157,020 - $253,259	-38,963 Reduced 74.86%	13,083 $69,000
Q3 2019 Nov 14, 2019	SELL	$2.8 - $12.85 $139,347 - $639,505	-49,767 Reduced 48.88%	52,046 $224,000
Q2 2019 Aug 16, 2019	BUY	$10.6 - $13.12 $30,867 - $38,205	2,912 Added 2.94%	101,813 $1.21 Million
Q2 2019 Aug 14, 2019	BUY	$10.6 - $13.12 $843,124 - $1.04 Million	79,540 Added 410.83%	98,901 $1.18 Million
Q1 2019 May 15, 2019	SELL	$9.96 - $13.44 $1.58 Million - $2.13 Million	-158,591 Reduced 89.12%	19,361 $241,000
Q4 2017 Feb 14, 2018	BUY	$10.51 - $17.22 $644,504 - $1.06 Million	61,323 Added 52.58%	177,952 $2.99 Million
Q3 2017 Nov 14, 2017	BUY	$10.14 - $14.85 $1.18 Million - $1.73 Million	116,629	116,629 $1.63 Million

Others Institutions Holding GLYC

# of Institutions

Shares Held

36.8M

Call Options Held

969K

Put Options Held

636K

View Full List

About GLYCOMIMETICS INC

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $17.3M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

More about GLYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Glycomimetics Inc Transaction History